263 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
POSTER SESSIONS
255
German language Session
006
Drug monitoring in the therapy with aripipra-
zole-depot – clinical efficacy, side effects and blood
levels
Richard Serfling, Germany
Stefan Metz
007
Aripiprazole long acting injectable: continuation
rates and patterns of treatment discontinuation
Sergio Sanchez Alonso, Spain
Constanza Vera Varela, Marta Migoya, Fanny Cegla,
Nora Palomar, Marina Llaguno, Alba Sedano Capdevila,
Silvia Vallejo Oñate, Adrián López, Manuel Vásquez,
Elsa Arrua Duarte, Leticia Serrano Marugán, Santiago
Ovejero Garcia, Raquel Alvarez García, Laura Mata
Iturralde
008
Long-term effectiveness of aripiprazole
once-monthly is maintained in the QUALIFY
extension study
Rebecca Zingsheim, Germany
Dieter Naber, Ross A. Baker, Anna Eramo, Carlos Forray,
Karina Hansen, Christophe Sapin, Timothy Peters-
Strickland, Anna-Greta Nylander, Peter Hertel, Simon
Nitschky Schmidt, Jean-Yves Loze, Steven G. Potkin
009
Prescription trends of aripiprazole long acting
injectable
Laura Mata Iturralde, Spain
Raquel Alvarez, Santiago Ovejero Garcia, Leticia Serrano
Marugán, Elsa Arrua, Alba Sedano Capdevila, Silvia
Vallejo Oñate, Constanza Vera Varela, Marta Migoya,
Nora Palomar, Adrián López, Fanny Cegla, Marina
Llaguno, Manuel Vásquez, Sergio Sanchez Alonso
010
Efficacy of aripiprazole long-acting injectable
in acute non-schizophrenic psychotic inpatients:
a naturalistic study
Raquel Alvarez García, Spain
Fanny Cegla, Marta Migoya, Nora Palomar,
Laura Mata Iturralde, Sergio Sanchez-Alonso,
Santiago Ovejero Garcia
011
Pyridoxamine, a novel treatment for negative
symptoms of schizophrenia
Mitsuhiro Miyashita, Japan
Makoto Arai, Takashi Dan, Kazuya Toriumi, Yasue
Horiuchi, Akiko Kobori, Kazuhiro Suzuki, Masanari
Itokawa, Toshio Miyata
012
Administration of high-dose pyridoxamine to
adult mice
Makoto Arai, Japan
Kazuya Toriumi, Mitsuhiro Miyashita, Yasue Horiuchi,
Genevieve Konopka, Masanari Itokawa, Takashi Dan,
Toshio Miyata
013
The treatment effects on social functioning and
employment status in patients treated with paliperi-
done palmitate under clinical settings
Ryoko Nakagawa, Japan
Takashi Ohnishi, Toshio Yamaoka, Tokiko Touma, Keiko
Imai, Kenichi Noguchi
014
Paliperidone palmitate 3-monthly formulation
in schizophrenia – baseline interim analysis of a
naturalistic, 52-week, prospective study
Ludger Hargarter, Germany
Paul Bergmans, Irina Usankova, Pierre Cherubin
015
Immunomodulating effects of risperidone
Olga Lobacheva, Russia
Valentina Nikitina, Elena Kornetova, Tamara Vetlugina,
Arkady Semke
016
The metabolic state differences on the long
term treatment with risperidone, olanzapine or
clozapine
Irena Popovic, Serbia
Dragan Milosevic, Snezana Vladejic
017
Olanzapine/fluoxetine combination in treatment
of residual type schizophrenia
Olgha Kukhianidze, Republic of Georgia
Nino Okribelashvili
018
Inhaled loxapine avoids and reduces the
physical restraint in psychotic agitation
Santiago Ovejero Garcia, Spain
Miren Iza, Constanza Vera, Silvia Vallejo, Laura Mata,
Raquel Alvarez
P-10
Poster Session
13:30– 15:00
|
Hall Budapest
TOPIC 3:
Psychotic disorders
Psychotic disorders: psychotherapy and other
interventions
Chair:
Georg Juckel, Germany
001
Quality of life in patients with schizophrenia
Stojan Bajraktarov, Republic of Macedonia
Slavica Arsova
002
The association between duration of untreated
psychosis and treatment delay on the outcomes of
prolonged early intervention in psychotic disorders
Nikolai Albert, Denmark
003
Effectiveness of coordinated specialty care
versus usual or modular care for patients with early
psychosis: systematic review, meta-analysis and
meta-regression-analysis
Britta Galling, Germany
Christoph U. Correll